Clinical Trial Comparison of Dupilumab and Nemolizumab for Prurigo Nodularis FDA-Approved Biologic Therapy Selection in Prurigo Nodularis. [PDF]
Robertson A, Rohan C.
europepmc +1 more source
Use of dupilumab in the management of refractory prurigo nodularis in an immunosuppressed double transplanted patient. [PDF]
Valenzuela Godoy D +2 more
europepmc +1 more source
Dupilumab Treatment Provides Multidimensional Benefits in Patients with Prurigo Nodularis. [PDF]
Ständer S +8 more
europepmc +1 more source
Real-world Clinical Efficacy and Patient-reported Treatment Satisfaction of Nemolizumab Treatment in Prurigo Nodularis. [PDF]
Mima Y, Yamamoto M, Iozumi K.
europepmc +1 more source
Somatic mutations reveal hyperactive Notch signaling in prurigo nodularis. [PDF]
Rajeh A +24 more
europepmc +1 more source
Prurigo nodularis: case series of 28 Brazilian patients treated with psychotropic medications. [PDF]
Gerlero P +3 more
europepmc +1 more source
Acute T-cell leukemia/lymphoma presenting with leukemia cutis mimicking prurigo nodularis. [PDF]
Elghannam M +3 more
europepmc +1 more source
Guidelines for the diagnosis and treatment of prurigo nodularis. [PDF]
Zhang L +29 more
europepmc +1 more source
Rapid itch relief with the biologic agent nemolizumab in Atopic dermatitis and Prurigo nodularis: Promise, complexity and clinical implications. [PDF]
Lukaschek K, Weisshaar E.
europepmc +1 more source
Efficacy and Safety of Conventional and Biologic Therapies in Prurigo Nodularis: A Systematic Review and Meta-Analysis. [PDF]
Lancz A +7 more
europepmc +1 more source

